SCHEMBL17413865

SCHEMBL17413865

C=Cc1ccc(-c2cc(OC)ncc2F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 1/20 0.42
▸ ALOX5AP P20292 1/20 0.40
▸ ERN1 O75460 1/20 0.39
▸ RPS6KA3 P51812 1/20 0.39
▸ BACE1 P56817 2/20 0.38
▸ TDO2 P48775 1/20 0.36
▸ FFAR1 O14842 5/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.35
▸ TUBB4A P04350 1/20 0.35
▸ TUBB P07437 1/20 0.35
▸ TUBA3C P0DPH7 1/20 0.35
▸ TUBA1B P68363 1/20 0.35
▸ TUBA4A P68366 1/20 0.35
▸ TUBB4B P68371 1/20 0.35
▸ TUBB3 Q13509 1/20 0.35
▸ TUBB2A Q13885 1/20 0.35
▸ TUBB8 Q3ZCM7 1/20 0.35
▸ TUBA3E Q6PEY2 1/20 0.35
▸ TUBA1A Q71U36 1/20 0.35
▸ TUBA1C Q9BQE3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17503163 0.85 ERN1 (0.47) AAK1ALOX5APERN1RPS6KA3BACE1
SCHEMBL15990260 0.83 AAK1 (0.43) AAK1ALOX5APERN1RPS6KA3BACE1
SCHEMBL15990525 0.83 AAK1 (0.48) AAK1ALOX5APERN1RPS6KA3BACE1
SCHEMBL17408897 0.80 PTGS2 (0.38) AAK1RPS6KA3TDO2FFAR4TLR9
SCHEMBL19181794 0.79 AAK1 (0.41) AAK1ALOX5APERN1RPS6KA3BACE1
SCHEMBL17503151 0.79 AAK1 (0.41) AAK1ALOX5APERN1RPS6KA3BACE1
SCHEMBL15990522 0.78 ERN1 (0.38) AAK1ALOX5APERN1RPS6KA3BACE1
SCHEMBL17504867 0.77 AAK1 (0.42) AAK1ALOX5APERN1RPS6KA3BACE1
SCHEMBL19181798 0.76 AAK1 (0.41) AAK1ALOX5APERN1RPS6KA3BACE1
SCHEMBL29454649 0.75 MAP4K4 (0.49) AAK1FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9840512-B2 Antidiabetic bicyclic compounds MERCK SHARP & DOHME CORP. (US) 2017-12-12 — — US disclosed
US-20160002255-A1 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC 2016-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002255-A1 ANTIDIABETIC BICYCLIC COMPOUNDS GPR119, GPR65, GLP1R AAK1 1030/4885ALOX5AP 1576/4885ERN1 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback